Orlistat
Double-Blind, Multi-Center, Randomized Study to Assess the Efficacy and Safety of Velneperit (S-2367) and Orlistat Administered Individually or Combined With a Reduced Calorie Diet
Empros Pharma AB · Phase 2 · Completed · Enrollment 486
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Placebos. | n/r | n/r | n/r | n/r |
| Velneperit 400 mg | n/r | n/r | n/r | n/r |
| Orlistat 120 mg | n/r | n/r | n/r | n/r |
| Velneperit 400 mg + Orlistat 120 mg | n/r | n/r | n/r | n/r |
Not shown
- Placebos.: endpoint not reported
- Velneperit 400 mg: endpoint not reported
- Orlistat 120 mg: endpoint not reported
- Velneperit 400 mg + Orlistat 120 mg: endpoint not reported